Pharmaceuticals Search Engine [selected websites]


Blog Archive

Thursday, December 27, 2007

ExonHit Therapeutics, Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease

20 December 2007 - ExonHit Therapeutics, a drug and diagnostic discovery company, announced today that it has obtained a regulatory approval to initiate a Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease . EHT 0202 is a compound, with a novel mechanism of action, which has shown benefits on memory and neuronal loss... ExonHit's Press Release -

Tuesday, December 18, 2007

EDAP's Ablatherm HIFU treatments, Phase II/III U.S. Clinical Study program seeking FDA approval

LYON, France, Dec. 5, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP), the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announced the launch of Ablatherm HIFU treatments at Vanderbilt University Medical Center, Nashville, TN. The treatments are part of EDAP's ongoing Phase II/III U.S. Clinical Study program seeking FDA approval as the first HIFU device for prostate cancer in the United States... EDAP's Press Release -

Monday, December 17, 2007

Stallergenes and Protein Expert, Partnership for producing mites recombinant allergens

December 12, 2007 - STALLERGENES S.A and Protein’eXpert S.A. announce they have signed a partnership agreement for developing and pharmaceutically producing mites recombinant allergens .
The partnership is part of the STALLERGENES “Enhanced Allergens” innovation programme for a recombinant protein treatment for sublingual desensitisation of allergy to mites. This second-generation treatment is made up of the recombinant allergens Der p 1 and Der p 2 in the form of a fusion protein, combined with an adjuvant and/or a mucoadhesive formulation for facilitating recognition of the allergen by the immune system... Stallergenes' Press Release - Version Française

Monday, December 3, 2007


Paris, France - November 8, 2007 - ExonHit Therapeutics, a drug and diagnostic discovery company, has completed a prototype of the first blood-based Alzheimer's disease test. The company expects to have this test certified and to provide it as a service in its GLP (Good Laboratory Practices) compliant laboratories to the pharmaceutical industry as early as 2009... ExonHit's Press Release - Communiqué de Presse ExonHit -

Thursday, November 22, 2007

BioAlliance Pharma, pivotal phase III clinical trial of Loramyc , treatment of oropharyngeal candidiasis

Paris, November 16, 2007 – BioAlliance Pharma SA (Euronext Paris – ticker code BIO), today announced that it had successfully completed patient enrolment in the pivotal phase III clinical trial performed with a view to registering Loramyc® in the US, for the treatment of oropharyngeal candidiasis... [PDF] BioAlliance's Press Release - PDF en Français -

NicOx’ naproxcinod phase 3 results

Sophia Antipolis, France, Nov. 22, 2007 - ...Naproxcinod is in phase 3 clinical development for the treatment of the signs and symptoms of osteoarthritis. Two remaining pivotal phase 3 trials for naproxcinod (the 302 and 303 studies) are currently ongoing and efficacy results are expected to be reported in mid-2008. The Company will conduct a statistical analysis according to a predefined plan on the pooled OBPM data from the three phase 3 studies (301, 302 and 303), following the completion of the 302 and 303 studies. NicOx anticipates filing a New Drug Application for naproxcinod in the United-States during the first quarter of 2009... [PDF] NicOx’ Press Release - PDF en Français -

Tuesday, October 23, 2007


Marseille, October 22, 2007 - Innate Pharma SA, a biopharmaceutical company developing first-in-class drugs targeting the innate immune system, today announced that it has received approval from the French authorities to start an exploratory Phase II (“Phase IIa”) clinical trial in chronic myeloid leukemia* (“CML”) with IPH 1101, the lead drug candidate of its γδ T cell platform... Innate Pharma's Press Release [PDF]- Communiqué de Presse d'Innate Pharma en français [PDF]-

BioAlliance Pharma, promising in vivo results for a New Entity

Paris, October 22, 2007 - BioAlliance Pharma SA (Euronext Paris - Code Isin: FR0010095596 -BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance, said it will present the first promising in vivo results for its New Entity AMEP, invasive melanoma drug candidate (BA 015 program), at the 15th congress of the European Society of Gene and Cell Therapy, Rotterdam, October 27-30... BioAlliance Pharma's Press Release [PDF] - Communiqué de Presse de BioAlliance Pharma en français (PDF]-

Friday, October 19, 2007

Flamel Technologies, Positive Results of a Phase I Trial

October 18, 2007 - Flamel Technologies (NASDAQ:FLML) announced positive preliminary Phase I data from a trial comparing the safety, tolerability, and long-acting activity of FT-105 versus Lantus , an approved basal insulin. FT-105 is a long-acting recombinant insulin* formulation that uses a new microparticulate adaptation of Flamel's proprietary Medusa® nanoparticle delivery system... Flamel Technologies' Press Release-

bioMérieux’s VIDAS® B·R·A·H·M·S PCT® Assay A First Indication for Sepsis Risk Assessment in the ICU

Oct. 18, 2007 - bioMérieux (Euronext: BIM), a world leader in the field of in vitro diagnostics, has received 510(k) clearance from the U.S. Food and Drug Administration to market VIDAS® B·R·A·H·M·S PCT®. The test will be used with critically ill patients on their first day of admission to the Intensive Care Unit (ICU) as an aid to assess their risk for progression to severe sepsis and septic shock... bioMérieux's Press Release -

Thursday, October 18, 2007


October 17th, 2007 - Vivalis (Euronext : VLS) announces having granted rights to SANOFI-AVENTIS to evaluate EBx® cell lines, cell substrates derived from avian embryonic stem cells, for the production of monoclonal antibodies... Vivalis' Press Release-

Wednesday, October 10, 2007

Biospace med, Total Solution to Orthopedic Imaging

Oct. 9, 2007 - Biospace med announced that it has received 510k clearance from the Food and Drug Administration (FDA) to market EOS, a new digital Xray imager in the United States for 2D imaging use. EOS 2D|3D technology is part of a total solution to orthopedic imaging allowing images to be obtained with a low dose of radiation and is capable of long length digital imaging, permitting full-body, uninterrupted digital imaging with a single scan...Biospace med's Press Release -

Tuesday, October 9, 2007

bioMerieux , Diagnosis and Prognosis of Heart Failure

October 1, 2007. bioMérieux, a global leader in the field of in vitro diagnostics, announces the launch of VIDAS® NT-proBNP, a CE-approved test that helps the diagnosis and prognosis of heart failure, developed by the company following a licensing agreement signed with Roche Diagnostics... bioMérieux's Press Release-

Tuesday, October 2, 2007

Transgene, therapeutic vaccine candidate TG4040 development program against chronic hepatitis C

Strasbourg, France, October 1, 2007 – Transgene S.A. (Eurolist Paris: FR0005175080) announces today that the first patients have been enrolled in a Phase I trial in Canada of its therapeutic vaccine candidate TG4040 (MVA-HCV). The trial is expected to treat approximately 24 patients that are chronically infected with the Hepatitis C Virus (HCV) and who have relapsed after standard treatment of Ribavirin and Pegylated-Interferon Alpha... Transgene's Press Release [PDF] -
Communiqué de Presse de Transgene [PDF en français] -

Friday, September 28, 2007

CEA and Proteus, Immuno’line™ for evaluating the immunogenicity of therapeutic proteins

Nimes, France, Sept 26, 2007 - Protéus announces the launching of "Immuno'line™", a new range of services which is marketed by its PSI (Proteus Services for Industry) division..Immuno'Line™ offers to the pharmaceutical industry new tools to evaluate the risks that a therapeutic protein candidate would induce an immune response and to determine the epitopes associated with such immunogenicity...This technology has been developed by CEA-DSV (French Commission for Atomic Energy – Life Science Division) thanks to the expertise of its department of protein engineering (Institute of Biology and Technologies - IBITECs based in Saclay)... Proteus' Press Release -

Stentys, Stentys Bifurcated Drug-Eluting Stent

PARIS-Sept. 24, 2007--Stentys announced today that its bifurcated stent was successfully implanted yesterday into a 56-year-old male patient at the HELIOS Klinikum Siegburg in Siegburg, Germany.Stentys has developed the world's first next-generation dedicated drug-eluting stent for treatment of blocked coronary artery bifurcations so that hundreds of thousands of patients might avoid open-chest surgery.... Stentys' Press Release [PDF] -

FraBioPosition, the blog dedicated to the french biotech

The aim of the Blog "FraBioPosition" is to share information found in the french life sciences companies websites which could be interesting to follow : new medical devices, pharmaceuticals, treatments, clinical trials...